



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Bureau for Medical Services
Office of Pharmacy Services
350 Capitol Street - Room 251

Charleston, West Virginia 25301-3706
Phone: (304) 558-1700 - Fax: (304) 558-1542

Earl Ray Tomblin
Governor

Rocco S. Fucillo
Cabinet Secretary

Pharmaceutical and Therapeutics Committee

April 24, 2013

Location: Diamond, Rooms B10 and B11

Time: 2:00 PM – 5:00 PM

Charleston, WV 25301

(304) 558-1700

MINUTES

Members Present:

Scott Brown, R.Ph.
Michael Grome, PA-C
Bradley Henry, M.D.
Tom Kines, R.Ph.
Steven R. Matulis, M.D, Chairperson
Amelia McPeak, D.O.
Harriet Nottingham, R.Ph.
Robert Stanton, Pharm.D.

Members Not Present:

Jeffrey V. Ashley, M.D.
David Avery, M.D.
Rodney L. Fink, D.O.

DHHR/BMS Staff Present:

Peggy King, R.Ph., Pharmacy Director
Vicki Cunningham, R.Ph., DUR Coordinator
Gail Goodnight, R.Ph., Drug Rebate Program
Director
William Hopkins, Pharmacy Operations Manager
Richard D. Sorvig, Administrative Assistant

**Contract Staff/Magellan Medicaid
Administration (MMA) Staff Present:**

Chris Andrews, Pharm.D.
Nina Bandali, Pharm.D.
Giovannino Perri, M.D.

Other Contract Staff/State Staff Present:

Steve Small, R.Ph., MS, Director, Rational Drug
Therapy Program

I. Call to Order

Dr. Steven Matulis, chairperson, called the meeting to order at 2:11PM. Dr. Matulis announced the resignation of Terri Dunsworth from the P&T Committee as of yesterday.

II. Welcome and Introductions

All parties seated at the table introduced themselves including the two new members, Dr. Bradley Henry and Tom Kines.

III. Housekeeping Items/Updates

A. Comments from BMS

Ms. Peggy King stated that all clinical and financial information for any drug on the agenda must be received by Magellan 60 days prior to the meeting date for all quarterly meetings except the annual meeting in October. This information will be added to the FAQs on the PDL website. Deadlines have already been established for the October meeting for the SSDC pool.

B. Approval of the January 30, 2013 Minutes

Dr. Matulis asked for approval of the minutes from the January 30, 2013 P&T meeting. A motion was made and seconded; the motion carried to approve the minutes as submitted.

C. PDL Compliance/Generic Percent Report Updates

Dr. Nina Bandali reported that the overall PDL compliance for Q4 2012 was 95.7% and the overall generic utilization rate for Q4 2012 was 75.6%.

IV. Public Comments

Kent Hunter, Pfizer, spoke in favor of Eliquis and Quillivant XR.

Carol Spelman, Aegerian, spoke in favor of Juxtapid.

Chris Phelan, Bausch & Lomb, spoke in favor of Lotemax gel.

V. Executive session

The motion was made and seconded to adjourn to executive session for confidential pricing discussion. A vote was taken and the motion was approved at 2:30PM. The meeting resumed at 3:16PM.

VI. Old Business

None

VII. New Business

A. New Generics

Dr. Bandali explained to the P&T Committee that the following generics are new to the market and staturesd as nonpreferred, citing financial reasoning:

mupirocin cream (generic for Bactroban cream)

fenofibrate (generic for Antara)

buprenorphine/naloxone tablets (generic for Suboxone tablets)

The motion to approve the new generics as presented was made and seconded. A vote was taken and the motion was approved.

C. New Drug Reviews

1. Onmel

MMA recommended that Onmel be made a non-preferred drug in the Antifungals, Oral category.

ANTIFUNGALS (Oral)		
	clotrimazole fluconazole* ketoconazole nystatin terbinafine ^{CL}	ANCOBON (flucytosine) DIFLUCAN (fluconazole) flucytosine GRIFULVIN V TABLET (griseofulvin) griseofulvin GRIS-PEG (griseofulvin) itraconazole LAMISIL (terbinafine) MYCELEX (clotrimazole) MYCOSTATIN Tablets (nystatin) NIZORAL (ketoconazole) NOXAFIL (posaconazole) ONMEL (itraconazole) ORAVIG (miconazole) SPORANOX (itraconazole) VFEND (voriconazole) voriconazole

2. Vascepa

MMA recommended that Vascepa be made a non-preferred drug in the Lipotropics, Other (Non-statins), Fatty Acids category.

LIPOTROPICS, OTHER (Non-statins)^{AP}		
BILE ACID SEQUESTRANTS		
	cholestyramine colestipol tablets	COLESTID (colestipol) colestipol granules KYNAMRO (mipomersen) ^{NR} QUESTRAN (cholestyramine) WELCHOL (colesevelam)
CHOLESTEROL ABSORPTION INHIBITORS		
	ZETIA (ezetimibe) ^{AP}	
FATTY ACIDS		
		LOVAZA (omega-3-acid ethyl esters) ^{AP} VASCEPA (icosapent ethyl)
FIBRIC ACID DERIVATIVES		
	fenofibrate 54mg & 160mg fenofibrate micronized 67mg, 134mg & 200mg gemfibrozil TRICOR (fenofibrate nanocrystallized)	ANTARA (fenofibrate) FENOGLIDE (fenofibrate) FIBRICOR (fenofibric acid) fenofibrate 43mg, 130mg

	TRILIPIX (fenofibric acid)	fenofibrate nanocrystallized 48mg, 145mg fenofibric acid LIPOFEN (fenofibrate) LOFIBRA (fenofibrate) LOPID (gemfibrozil) TRIGLIDE (fenofibrate)
NIACIN		
	niacin NIACOR (niacin) NIASPAN (niacin) SLO-NIACIN (niacin)	

3. Ilevro

MMA recommended that Ilevro be made a non-preferred drug in the Ophthalmic Anti-Inflammatories category.

OPHTHALMIC ANTI-INFLAMMATORIES		
	dexamethasone diclofenac fluorometholone flurbiprofen ketorolac NEVANAC (nepafenac) prednisolone acetate	ACULAR (ketorolac) ACULAR LS (ketorolac) ACUVAIL (ketorolac tromethamine) ^{AP} BROMDAY (bromfenac) bromfenac DUREZOL (difluprednate) ^{AP} FLAREX (fluorometholone) FML (fluorometholone) FML FORTE (fluorometholone) FML S.O.P. (fluorometholone) ILEVRO (nepafenac) LOTEMAX (loteprednol) MAXIDEX (dexamethasone) OMNIPRED (prednisolone) OZURDEX (dexamethasone) PRED FORTE (prednisolone) PRED MILD (prednisolone prednisolone sodium phosphate) PROLENSA (bromfenac) RETISERT (fluocinolone) TRIESENCE (triamcinolone) VEXOL (rimexolone) XIBROM (bromfenac)

4. Giazio

MMA recommended that Giazio be made non-preferred in the Ulcerative Colitis Agents category.

ULCERATIVE COLITIS AGENTS ^{AP}		
ORAL		
	APRISO (mesalamine) ASACOL (mesalamine) 400mg balsalazide DELZICOL (mesalamine) DIPENTUM (olsalazine) PENTASA (mesalamine) 250mg sulfasalazine	ASACOL HD (mesalamine) AZULFIDINE (sulfasalazine) COLAZAL (balsalazide) GIAZIO (balsalazide) LIALDA (mesalamine) PENTASA (mesalamine) 500mg

RECTAL	
CANASA (mesalamine) mesalamine	mesalamine kit ROWASA (mesalamine) SF ROWASA (mesalamine)

5. Oxtellar XR

Dr. Matulis stated that Oxtellar XR will be reviewed during the August meeting since all information was not received on time.

6. Lotemax Gel

MMA recommended that Lotemax gel be made non-preferred in the Ophthalmic Anti-Inflammatories category.

OPHTHALMIC ANTI-INFLAMMATORIES	
dexamethasone diclofenac fluorometholone flurbiprofen ketorolac NEVANAC (nepafenac) prednisolone acetate	ACULAR (ketorolac) ACULAR LS (ketorolac) ACUVAIL (ketorolac tromethamine) ^{AP} BROMDAY (bromfenac) bromfenac DUREZOL (difluprednate) ^{AP} FLAREX (fluorometholone) FML (fluorometholone) FML FORTE (fluorometholone) FML S.O.P. (fluorometholone) ILEVRO (nepafenac) LOTEMAX (loteprednol) MAXIDEX (dexamethasone) OMNIPRED (prednisolone) OZURDEX (dexamethasone) PRED FORTE (prednisolone) PRED MILD (prednisolone prednisolone sodium phosphate PROLENSA (bromfenac) ^{NR} RETISERT (fluocinolone) TRIESENCE (triamcinolone) VEXOL (rimexolone) XIBROM (bromfenac)

7. Eliquis

MMA recommended that Eliquis be made non-preferred in the Anticoagulants, Oral category.

ANTICOAGULANTS	
INJECTABLE^{CL}	
FRAGMIN (dalteparin) LOVENOX (enoxaparin)	ARIXTRA (fondaparinux) enoxaparin fondaparinux INNOHEP (tinzaparin)
ORAL	
COUMADIN (warfarin) PRADAXA (dabigatran) ^{AP} warfarin XARELTO (rivaroxaban) ^{AP}	ELIQUIS (apixaban)

7. Quillivant XR

MMA recommended that Quillivant XR be made non-preferred in the Stimulants and Related Agents, Non-Amphetamine category.

STIMULANTS AND RELATED AGENTS		
AMPHETAMINES		
	amphetamine salt combination IR dextroamphetamine VYVANSE (lisdexamfetamine)	ADDERALL (amphetamine salt combination) ADDERALL XR (amphetamine salt combination) amphetamine salt combination ER DESOXYN (methamphetamine) DEXEDRINE (dextroamphetamine) dextroamphetamine ER DEXTROSTAT (dextroamphetamine) methamphetamine PROCENTRA (dextroamphetamine)
NON-AMPHETAMINE		
	DAYTRANA (methylphenidate) FOCALIN (dexmethylphenidate) FOCALIN XR (dexmethylphenidate) guanfacine INTUNIV (guanfacine extended-release) METADATE CD (methylphenidate) METHYLIN CHEWABLE TABLETS, SOLUTION (methylphenidate) methylphenidate methylphenidate ER (generic Concerta, Ritalin SR, Metadate ER, Methylin ER) STRATTERA (atomoxetine)	CONCERTA (methylphenidate) dexmethylphenidate KAPVAY ER (clonidine) METADATE ER (methylphenidate) methylphenidate solution methylphenidate CD methylphenidate ER (generic Ritalin LA) modafinil NUVIGIL (armodafinil) pemoline PROVIGIL (modafinil) QUILLIVANT XR (methylphenidate) RITALIN (methylphenidate) RITALIN LA (methylphenidate) RITALIN SR (methylphenidate)

8. Nesina, Kazano, Oseni

MMA recommended that Nesina, Kazano, Oseni all be made non-preferred in the Hypoglycemics, Incretin Mimetics/Enhancers, Oral category.

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS		
INJECTABLE		
		BYDUREON (exenatide) BYETTA (exenatide) SYMLIN (pramlintide) VICTOZA (liraglutide)
ORAL^{AP}		
	JANUMET (sitagliptin/metformin) JANUVIA (sitagliptin) JUVISYNC (sitagliptin/simvastatin) KOMBIGLYZE XR (saxagliptin/metformin)	JANUMET XR (sitagliptin/metformin) JENTADUETO (linagliptin/metformin)

	ONGLYZA (saxagliptin) TRADJENTA (linagliptin)	KAZANO (alogliptin/metformin) NESINA (alogliptin) OSENI (alogliptin/pioglitazone)
--	--	---

9. Rebif Rebidose

MMA recommended that Rebif Rebidose be made preferred in the Multiple Sclerosis Agents, Interferons category.

MULTIPLE SCLEROSIS AGENTS^{CL, AP}		
INTERFERONS		
	AVONEX (interferon beta-1a) AVONEX PEN (interferon beta-1a) BETASERON (interferon beta-1b) REBIF (interferon beta-1a) REBIF REBIDOSE (interferon beta-1a)	EXTAVIA (interferon beta-1b)
NON-INTERFERONS		
	COPAXONE (glatiramer)	AMPYRA (dalfampridine)* GILENYA (fingolimod) ** AUBAGIO (teriflunomide)***

10. Delzicol DR

MMA recommended that Delzicol DR be made preferred in the Ulcerative Colitis Agents category.

ULCERATIVE COLITIS AGENTS^{AP}		
ORAL		
	APRISO (mesalamine) ASACOL (mesalamine) 400mg balsalazide DELZICOL (mesalamine) DIPENTUM (olsalazine) PENTASA (mesalamine) 250mg sulfasalazine	ASACOL HD (mesalamine) AZULFIDINE (sulfasalazine) COLAZAL (balsalazide) GIAZO (balsalazide) LIALDA (mesalamine) PENTASA (mesalamine) 500mg
RECTAL		
	CANASA (mesalamine) mesalamine	mesalamine kit ROWASA (mesalamine) SF ROWASA (mesalamine)

The Committee requested that the recommendations of the new drug reviews be handled in a single motion. A motion was made, seconded, and approved to accept the recommendations by MMA for these new drugs.

VIII. Next Meeting

The next P&T meeting is scheduled for August 28, 2013 at 2PM-5PM in the Bureau for Medical Services' offices, Diamond Building, 350 Capitol Street, Charleston, WV.

IX. Other Business

Dr. Matulis stated that Renagel 800 mg is being proposed to be made preferred. He inquired as to the rationale. Dr. Bandali stated the decision was made due to concerns from the public and financial information. The motion to approve Renagel 800 mg as preferred was made and seconded. A vote was taken and the motion was approved.

Ms. King announced her retirement in July and thanked everyone for working with her throughout the years during her tenure at BMS. Ms. King then provided an update on the managed care rollout which occurred on April 1st. She stated that everything is going well including the support of the manufacturers. Manufacturer supplemental rebate contracts have been signed except one which has only been signed for terms of agreement until June 30th since CMS has provided approval of rates until this date. It is unlikely that CMS will provide approval of the rates immediately after July since CMS typically is delayed in doing this. If the contract cannot be negotiated then this manufacturer's products may be moved to nonpreferred. BMS will then bring this back to the Committee in August.

X. Adjournment

The meeting was adjourned at 3:33PM.